Pro-Infliximab provided equivalent therapeutic efficacy to Infliximab while maintaining mouse immunity against Listeria infection, leading to a significantly higher survival rate (71%) than that of the Infliximab treatment group (0%).
Published in PLoS Biology 2019 Jun 13;17(6):e3000286. doi: 10.1371/journal.pbio.3000286.